首页|二甲双胍与格列齐特对痛风合并2型糖尿病患者临床转归和血清尿酸盐的影响

二甲双胍与格列齐特对痛风合并2型糖尿病患者临床转归和血清尿酸盐的影响

扫码查看
目的 比较二甲双胍、格列齐特对痛风合并2型糖尿病患者临床转归、血清尿酸盐的影响.方法 选择2020年7月—2022年10月在本院就诊的痛风合并2型糖尿病患者94例,随机分为对照组和观察组,各47例.对照组采用格列齐特+别嘌呤醇治疗,观察组采用二甲双胍+别嘌呤醇治疗.比较2组患者痛风症状评分、空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、血尿酸(sUA)、C反应蛋白(CRP)、血沉(ESR).结果 治疗后,对照组疼痛、肿胀、压痛、活动受限、总分分别为(1.23 土 0.39)分、(1.08±0.26)分、(1.21±0.28)分、(0.95±0.30)分和(4.47±1.14)分,观察组分别为(0.93±0.28)分、(0.85±0.30)分、(0.91±0.21)分、(0.74±0.28)分和(3.43±1.05)分,差异均有统计学意义(t值分别为4.146、3.972、4.215、4.196、6.082,P均<0.05).治疗后对照组sUA、CRP、ESR分别为(387.43±50.15)μmol/L、(15.40±3.63)mg/L、(28.63±8.59)mm/h,观察组分别为(354.40±39.67)μmol/L、(12.05±2.47)mg/L、(21.54±5.40)mm/h,差异均有统计学意义(t值分别为8.640、5.175、7.628,P均<0.05).治疗后对照组FPG、2hPG、HbA1c分别为(7.13±0.81)mmol/L、(1 1.32±1.86)mmol/L、(7.43±1.02)%,观察组分别为(6.65±0.67)mmol/L、(10.16±1.34)mmol/L、(6.85±0.89)%,差异均有统计学意义(t值分别为2.825、2.739、2.493,P均<0.05).结论 二甲双胍联合别嘌呤醇可进一步改善痛风合并2型糖尿病患者的疼痛、肿胀、压痛、活动受限等临床症状,降低患者的sUA、CRP、ESR 水平.
Comparison of the effects of metformin and gliclazide on clinical out-comes and serum urate in patients with gout and type 2 diabetes
Objective This study was aimed at comparing the effects of metformin and gliclazide on clinical out-comes and serum urate in patients with gout and type 2 diabetes.Methods A total of 94 patients with gout and type 2 diabetes who visited our hospital between July 2020 and October 2022 were studied.Through randomization,47 patients each were placed in a control group and an observation group.The control group was treated with gliclazide and allopurinol,whereas the observation group was treated with metformin and allopurinol.The gout symptom score,fasting blood glucose(FBG),2-hour postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),blood uric acid(sUA),C-reactive pro-tein(CRP),erythrocyte sedimentation rate(ESR)in both groups were observed.Results After treatment,the control group reported pain,swelling,tenderness,limited mobility,and total scores of 1.23±0.39,1.08±0.26,1.21±0.28,0.95±0.30,and 4.47±1.14,respectively.The observation group reported pain,swelling,tenderness,limited mobility,and total scores of 0.93±0.28,0.85±0.30,0.91±0.21,0.74±0.28,and 3.43±1.05,respectively.The differences between groups were statistically significant(t-values:4.146,3.972,4.215,4.196,and 6.082,respectively;all P<0.05).After treatment,the control group had sUA,CRP,and ESR levels of 387.43±50.15 μmol/L,15.40±3.63 mg/L,and 28.63±8.59 mm/h,respectively.The observation group had sUA,CRP,and ESR levels of 354.40±39.67 μmol/L,12.05±2.47 mg/L,and 21.54±5.40 mm/h,respectively.The differences between groups were statistically significant(t-values:8.640,5.175,and 7.628,respectively;all P<0.05).After treatment,the control group had FPG,2 hPG,and HbA1c levels of 7.13±0.81 mmol/L,11.32±1.86 mmol/L,and(7.43±1.02)%,respectively.The observation group had FPG,2 hPG,and HbA1c levels of 6.65±0.67 mmol/L,10.16±1.34 mmol/L,and(6.85±0.89)%,respectively.The differences between groups were statistically significant(t-values:2.825,2.739,and 2.493,respectively(all P<0.05).Conclusion Metformin combined with allopurinol ameliorates the clinical symptoms of patients with gout and type 2 diabetes,and decreases sUA levels with good safety.

GoutDiabetesMetforminGliclazideUric acid

李寒冰、甘宜璋

展开 >

滕州市中心人民医院内分泌科,山东滕州 277599

痛风 糖尿病 二甲双胍 格列齐特 尿酸

2024

中国校医
江苏省预防医学会 中华预防医学会

中国校医

影响因子:0.378
ISSN:1001-7062
年,卷(期):2024.38(4)
  • 5